Emerging targeted combinations in the management of breast cancer

R.J. Lee; A.C. Armstrong; A.M. Wardley

doi:10.2147/BCTT.S26771

Emerging targeted combinations in the management of breast cancer

R.J. Lee, A.C. Armstrong, A.M. Wardley

Research output: Contribution to journal › Article › peer-review

Abstract

The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.

Original language	Undefined
Pages (from-to)	61-72
Number of pages	12
Journal	Breast Cancer: Targets and Therapy
Volume	13
Issue number	5
DOIs	https://doi.org/10.2147/BCTT.S26771
Publication status	Published - 2013

Keywords

breast cancer
receptor
targeted therapy
tyrosine kinase

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/BCTT.S26771

Cite this

@article{4615f605e9c34956af2c299381ad8411,

title = "Emerging targeted combinations in the management of breast cancer",

abstract = "The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.",

keywords = "breast cancer, receptor, targeted therapy, tyrosine kinase",

author = "R.J. Lee and A.C. Armstrong and A.M. Wardley",

year = "2013",

doi = "10.2147/BCTT.S26771",

language = "Undefined",

volume = "13",

pages = "61--72",

journal = "Breast Cancer: Targets and Therapy",

publisher = "Dove Medical Press ",

number = "5",

}

TY - JOUR

T1 - Emerging targeted combinations in the management of breast cancer

AU - Lee, R.J.

AU - Armstrong, A.C.

AU - Wardley, A.M.

PY - 2013

Y1 - 2013

N2 - The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.

AB - The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.

KW - breast cancer

KW - receptor

KW - targeted therapy

KW - tyrosine kinase

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84889256571&partnerID=MN8TOARS

U2 - 10.2147/BCTT.S26771

DO - 10.2147/BCTT.S26771

M3 - Article

VL - 13

SP - 61

EP - 72

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

IS - 5

ER -

Emerging targeted combinations in the management of breast cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this